These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 16194413

  • 1. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
    Zhang GH, Hou FF, Zhang X, Liu QF.
    Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
    [Abstract] [Full Text] [Related]

  • 2. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 3. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P.
    N Engl J Med; 1996 Apr 11; 334(15):939-45. PubMed ID: 8596594
    [Abstract] [Full Text] [Related]

  • 4. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT, Huang YB, Lin MY, Chuang PF, Hwang SJ.
    Kaohsiung J Med Sci; 2012 Sep 11; 28(9):477-83. PubMed ID: 22974666
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of benazepril for advanced chronic renal insufficiency.
    Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW.
    N Engl J Med; 2006 Jan 12; 354(2):131-40. PubMed ID: 16407508
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
    Fan CM, Yan LR, Tao YK, Wang L, Li YQ, Gao MM, Wang YN, Li CX, Wang XW, Lu XL, Pang HM, Li YS.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan 12; 39(1):57-60. PubMed ID: 21418799
    [Abstract] [Full Text] [Related]

  • 7. [Effect of angiotensin II receptor antagonist (losartan) on renal function, serum potassium and blood pressure in patients with advanced renal failure: differences between patients with a serum creatinine (SCr) level higher than 3 mg/dl and those with a lower SCr level].
    Nakayama M, Tanno Y, Otsuka Y, Takahashi H, Ikeda M, Katoh N, Yokoyama K, Yamamoto H, Tokutome G, Hosoya T.
    Nihon Jinzo Gakkai Shi; 2002 Oct 12; 44(7):530-6. PubMed ID: 12476589
    [Abstract] [Full Text] [Related]

  • 8. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep 12; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 9. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial.
    Wang YJ, He LQ, Sun W, Lu Y, Wang XQ, Zhang PQ, Wei LB, Cao SL, Yang NZ, Ma HZ, Gao J, Li P, Tao XJ, Yuan FH, Li J, Yao C, Liu X.
    J Ethnopharmacol; 2012 Feb 15; 139(3):757-64. PubMed ID: 22178174
    [Abstract] [Full Text] [Related]

  • 10. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.
    Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Janin G, Zucchelli P.
    J Cardiovasc Pharmacol; 1999 Apr 25; 33 Suppl 1():S16-20; discussion S41-3. PubMed ID: 10028949
    [Abstract] [Full Text] [Related]

  • 12. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.
    Ardissino G, Viganò S, Testa S, Daccò V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, La Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM, ItalKid Project.
    Nephrol Dial Transplant; 2007 Sep 25; 22(9):2525-30. PubMed ID: 17526542
    [Abstract] [Full Text] [Related]

  • 13. Tolerability and efficacy of benazepril in cats with chronic kidney disease.
    King JN, Gunn-Moore DA, Tasker S, Gleadhill A, Strehlau G, Benazepril in Renal Insufficiency in Cats Study Group.
    J Vet Intern Med; 2006 Sep 25; 20(5):1054-64. PubMed ID: 17063696
    [Abstract] [Full Text] [Related]

  • 14. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X, Chen X, Liu S, Zhuang Y, Zhang Y.
    Zhonghua Nei Ke Za Zhi; 2002 Jun 25; 41(6):399-403. PubMed ID: 12137603
    [Abstract] [Full Text] [Related]

  • 15. Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
    Li XM, Cong HL, Li TT, He LJ, Zhou YJ.
    Chin Med J (Engl); 2011 Jul 25; 124(14):2101-6. PubMed ID: 21933609
    [Abstract] [Full Text] [Related]

  • 16. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
    Am J Hypertens; 2004 Jun 25; 17(6):495-501. PubMed ID: 15177521
    [Abstract] [Full Text] [Related]

  • 17. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
    Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K, CAP-KD Study Group.
    Am J Kidney Dis; 2009 Sep 25; 54(3):459-67. PubMed ID: 19615804
    [Abstract] [Full Text] [Related]

  • 18. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial.
    Halimi JM, Giraudeau B, Buchler M, Al-Najjar A, Etienne I, Laouad I, Bruyère F, Lebranchu Y.
    Clin Transplant; 2007 Sep 25; 21(2):277-84. PubMed ID: 17425758
    [Abstract] [Full Text] [Related]

  • 19. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 25; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 20. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Sep 25; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.